Key Publications
Thomas et al. A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease. Nature Immunology 2024; epub 22/10.2024.
Friedrich M & Pohin M & Jackson MA et al. IL-1-driven stromal-neutrophil interaction in deep ulcers identifies a pathotype of therapy non-responsive inflammatory bowel disease patients. Nature Medicine 2021; 27: 1970.
Friedrich M & Travis S. Shining a Light on Barrier Function. Gastroenterology 2023; 164(2):184.
Friedrich M & Pohin M & Powrie F. Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. Immunity 2019; 50:992.
West N & Hegazy A. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nature Medicine 2017; 23:579.
Korsunsky I & Wei K & Pohin M & Kim EY & Barone F. Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases. Med 2022; 3(7): 481.
Hackstein CP et al. A conserved population of MHC II-restricted, innate-like, commensal-reactive T cells in the gut of humans and mice. Nature Communications 2022; 13(1):7472.
Tillack C & Ehmann LM & Friedrich M et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63:567.
Friedrich M et al. Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease. Mucosal Immunology 2015; 8:943.
Demetriou P et al. A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals. Nature Immunology 2020; 21:1232.
Research groups
Matthias Friedrich
Dr. rer. biol. hum.
Group Leader (Wellcome Trust Career Development Award)
Gastrointestinal Pathophysiology - Translational Research and Experimental Medicine
Research
Our team is interested in the cellular and molecular mechanisms of chronic inflammation and fibrosis. Whilst the focus is on Inflammatory Bowel Diseases (IBDs), we aim to identify shared and distinct patho-mechanisms across organs. Combining cutting edge digital pathology and AI approaches, spatial/single-cell/bulk genomics and proteomics, highly multiplexed immunohistochemistry and flow cytometry, we profile large patient cohorts. This is complemented by mechanistic studies of in vivo disease models and in vitro organotypic tissue cultures. Current projects strive to personalise medical therapy in IBD, finding alternative treatments for fibrotic Crohn's disease, and establishing a molecular basis for symptoms in ulcerative colitis.
Team
Research Assistants:
Osheen Sharma (Lab Management)
Laboratory and Administrative Assistants:
Kate Hutton
Postdocs:
Simon Wölfel
Bin Li (co-supervised)
Hosuk Ryou (co-supervised)
Kristina Clark (Academic Clinical Lecturer, co-supervised)
DPhil students:
Zhi Wong (co-supervised)
Julia Pakpoor (co-supervised)
Clinical Fellows:
Khalid Shamiyah
Former lab members:
Kaiyang Song
Rahul Ravindran
Tom Hosack
Recent publications
-
Global Practices in Cardiac Imaging for Cardiac Sarcoidosis: A Survey Study of International Experts With Delphi Consensus
Journal article
Kafil TS. et al, (2025), Jacc Cardiovascular Imaging, 18, 679 - 692
-
CD4+ tissue-resident memory Th17 cells are a major source of IL-17A in Spondyloarthritis synovial tissue.
Journal article
Liu F. et al, (2025), Annals of the rheumatic diseases
-
Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy
Journal article
Tadros R. et al, (2025), Nature Genetics, 57, 530 - 538
-
Molecular signature of bowel urgency in Ulcerative Colitis
Journal article
Pakpoor J. et al, (2025), JOURNAL OF CROHNS & COLITIS, 19, i583 - i585
-
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
Journal article
Woelfel S. et al, (2025), Alimentary pharmacology & therapeutics, 61, 299 - 312